Floatz logo

Binimetinib

Lung Cancer

N.N. Petrov National Medical Research Center of OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

Binimetinib is also rated in:

metastatic malignant neoplasm in the colonDormant
BB
Indicative ·
70 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →